Urologic Oncology

The U-M Department of Urology Division of Urologic Oncology is comprised of nine fellowship-trained urologic oncologists with a vast array of expertise covering all aspects of urologic care. This includes treatment of:

  • bladder/upper tract urotelial cancer
  • complicated kidney cancers
  • high-risk prostate cancer
  • penile cancer
  • testis cancer
  • robotic prostatectomy
U-M Comprehensive Cancer Center

The Division's patients are assessed as individuals by our urologic oncologists, as well as by a  team of medical oncologists, radiation oncologists and pathologists. This multidisciplinary team allows for the design of specialized and personalized treatment plans that seek to optimize clinical outcomes. Specific approaches include:

  • nerve-sparing prostatectomy
  • robotic cystectomy and neobladder creation
  • retroperitoneal lymphadenectomy for testicular cancers
  • partial nephrectomy
  • all phases of clinical trials for all stages of urologic cancers

Patient care does not stop once treatment for prostate cancer ends. The Division of Urologic Oncology is active in the research on and delivery of prostate cancer survivorship, which seeks to support patients with any issues that arise after they overcome prostate cancer.

The UMHS Comprehensive Cancer Center works closely with the Division of Urologic Oncology, recognizing it as a "Program of Excellence" within the UMHS. The Cancer Center also partners with Urologic Oncology with the Prostate Cancer Survivorship Initiative.

Meet the Team:

David Christopher Miller MD

David Christopher Miller, M.D.

Professor, Urology
Chief, Dow Health Services Research, Urology
Medical Director for Strategic Planning and Business Development, Michigan Medicine